Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply by Authors.
Trock BJ, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, Vidal I, Glavaris SA, Guner G, Ertunc O, Kulac I, Baena Del Valle JA, Jones T, Han M, Partin AW, Cohen T, Stone S, De Marzo AM. Trock BJ, et al. Among authors: vidal i. J Urol. 2022 Dec;208(6):1192-1193. doi: 10.1097/JU.0000000000002922.02. Epub 2022 Dec 1. J Urol. 2022. PMID: 36349916 No abstract available.
Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.
Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, Allaf ME. Gorin MA, et al. Among authors: vidal i. J Urol. 2018 Jan;199(1):126-132. doi: 10.1016/j.juro.2017.07.070. Epub 2017 Jul 20. J Urol. 2018. PMID: 28736318 Free PMC article. Clinical Trial.
P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS. Maynard JP, et al. Among authors: vidal i. J Pathol. 2022 Feb;256(2):149-163. doi: 10.1002/path.5815. Epub 2021 Nov 25. J Pathol. 2022. PMID: 34652816 Free PMC article.
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.
Ouellet V, Erickson A; GAP1 UTMAs Contributing Investigators; Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, Bova GS, Lamminen T, Achtman AH, Buzza M, Kouspou MM, Bigler SA, Zhou X, Freedland SJ, Mes-Masson AM, Garraway IP, Trock BJ, Taimen P, Saad F, Mirtti T, Knudsen BS, De Marzo AM. Ouellet V, et al. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):715-727. doi: 10.1158/1055-9965.EPI-21-0600. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35131885 Free PMC article.
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy.
Trock BJ, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, Vidal I, Glavaris SA, Guner G, Ertunc O, Kulac I, Baena Del Valle JA, Jones T, Han M, Partin AW, Cohen T, Stone S, De Marzo AM. Trock BJ, et al. Among authors: vidal i. J Urol. 2022 Dec;208(6):1182-1193. doi: 10.1097/JU.0000000000002922. Epub 2022 Aug 25. J Urol. 2022. PMID: 36006048
Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.
Erak E, Oliveira LD, Mendes AA, Dairo O, Ertunc O, Kulac I, Baena-Del Valle JA, Jones T, Hicks JL, Glavaris S, Guner G, Vidal ID, Markowski M, de la Calle C, Trock BJ, Meena A, Joshi U, Kondragunta C, Bonthu S, Singhal N, De Marzo AM, Lotan TL. Erak E, et al. Among authors: vidal id. Mod Pathol. 2023 Oct;36(10):100247. doi: 10.1016/j.modpat.2023.100247. Epub 2023 Jun 10. Mod Pathol. 2023. PMID: 37307876
137 results